(lp0
S"Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today Motley Fool - Nov 9, 2016 Arrowhead stated that the U.S. Food and Drug Administration has verbally notified the company of the agency's decision to place a study called Heparc-2004 on hold.Arrowhead Stock Falls After FDA Places Hold on Clinical Trial - Xconomy"
p1
aS"Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today Motley Fool - Nov 30, 2016 It is a rough day to be an investor in Arrowhead Pharmaceuticals . Shares of the clinical-stage biotech are collapsing, falling more than 65% as of 11:36 a.m.Stock Update : Here's Why Shares of Arrowhead Pharmaceuticals Inc ... - Smarter Analyst"
p2
aS"What's Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown? Motley Fool - Nov 10, 2016 Things had been looking pretty good for Arrowhead Pharmaceuticals, Inc.  this year. Not anymore. Shares of the biotech plunged over 30% on Wednesday after the U.S.Chardan Weighs in on Biotech Stocks Novavax, Inc.  and Arrowhead ... - Smarter AnalystArrowhead Pharmaceuticals' Clinical Hold Woes Are Overblown - Seeking Alpha"
p3
aS'Company Update : Arrowhead Pharmaceuticals Inc Reports FQ1:17 Results Smarter Analyst - Feb 6, 2017 The 12-month average price target assigned to the stock is $2.00, which represents a slight upside potential from current levels. Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline&nbsp;...Arrowhead Pharmaceuticals, Inc.  Posts Quarterly Earnings Results - Sports Perspectives'
p4
aS'Analyst Downgrades: Arrowhead Pharmaceuticals Inc, Freeport-McMoRan Inc, and ... Schaeffers Research  - Nov 30, 2016 Analysts are weighing in on drugmaker Arrowhead Pharmaceuticals Inc , mining stock Freeport-McMoRan Inc , and real estate specialist Fang Holdings Ltd .'
p5
aS'Company Update : Arrowhead Pharmaceuticals Inc Announces Fiscal ... Smarter Analyst - Dec 14, 2016 Sentiment on the street is mostly neutral on ARWR stock. Out of 5 analysts who cover the stock, 4 suggest a Hold rating and one recommends to Buy the stock.'
p6
aS'Cantor Sees 100% Upside for Arrowhead Pharmaceuticals Inc  Shares Smarter Analyst - Aug 19, 2016 Cantor analyst Elemer Piros initiated coverage on shares of Arrowhead Pharmaceuticals Inc , with a Buy rating and price target of $15, which represents a 100% increase from where the shares last closed.What Caused Arrowhead Pharmaceuticals to Skyrocket 12.5% Today - Motley FoolArrowhead Pharmaceuticals Inc.  Continues Upward Journey - Scibility Media'
p7
aS'Arrowhead Pharmaceuticals Inc.  Soars 10.86% on January 31 Equities.com - Jan 31, 2017 Arrowhead Pharmaceuticals Inc.  had a good day on the market for Tuesday January 31 as shares jumped 10.86% to close at $1.94.'
p8
aS'Chardan Comments on Arrowhead Pharmaceuticals Inc  Following New ... Smarter Analyst - Sep 29, 2016 Arrowhead Pharmaceuticals Inc  shares are up nearly 6% as of this writing, after the RNAi therapeutics company announced a collaboration with Amgen  on two cardiovascular disease assets.Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations - PR Newswire Amgen &amp; Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations - Drug Discovery & Development'
p9
aS"Company Update : Arrowhead Pharmaceuticals Inc and Spring Bank ... Smarter Analyst - Oct 6, 2016 Arrowhead Pharmaceuticals Inc  and Spring Bank Pharmaceuticals, Inc.  announced an agreement to perform collaborative studies on Arrowhead's ARC-520 and Spring Bank's SB 9200, for the treatment of chronic&nbsp;..."
p10
a.